Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer
This study provides preclinical evidence of antigenicity and MHC-I compatibility of four prostate cancer-derived CTL epitopes using a transgenic mouse model. These findings support the advancement of these peptides as candidates for peptide-based immunotherapy in prostate cancer.
Authors
- Xiaolu Duan (ORCID: https://orcid.org/0000-0001-7885-1487)
- Yang Yang (ORCID: https://orcid.org/0000-0001-5306-7274)
- Tuxiong Huang
- Xuezhi Long
- Li Fu
- Y. Huang
- Yue Shu
- Zhipeng Wen
- Di Gu
- Yanni Xie
- Siqi Yang
Institutions
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Shenzhen University Health Science Center (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/dddt.s576346
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China